About Luxsol

Luxsol is one of the few treatments in the USA to be covered by a patent granted by the USPTO to treat Covid-19 virus and Influenza:

US Patent No. 11,000,545 on May 11, 2021

Luxsol

What is Luxsol? Luxsol is a suspension that is intended for use as a targeted treatment for respiratory illness associated with Covid-19 and influenza. It is not a pill or an injection. It is a spray through the mouth delivering drug directly to lungs using a nebulizer.

Side Effects

Side effects are unknown at this stage, as the drug has not entered human studies. However, based on human experience with Luxsol side effects are expected to be both rare and mild.

History of Luxsol

Luxsol was successfully tested in the treatment of Covid-19 in an In vitro study using Remdesivir as the positive control. Both drugs were equally effective killing the SARS-COV-2 virus.

Luxsol is one of the few treatments in the USA to be covered by a USPTO patent to treat Covid-19 virus and Influenza.

3V Medical Research Group developed Luxsol as a targeted therapeutic.